PCT



PATENT 4501-1016

## IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

CAMPBELL et al.

Conf. 9620

Application No. 10/530,209

Group 1615

Filed April 4, 2005

THERAPEUTIC USES OF -CASEIN  $A^2$  AND DIETARY SUPPLEMENT CONTAINING CASEIN  $A^2$ 

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

In compliance with Rules 1.97 and 1.98, and in ful-fillment of the duty of disclosure under Rule 1.56, the cited documents are made of record on the enclosed PTO Form-1449.

As the USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and patent publication for applications filed after June 30, 2003, copies of the cited U.S. references are <u>not</u> enclosed, as the present application is filed after June 30, 2003. Copies of the cited foreign patent documents and/or non-patent literature are enclosed.

A concise explanation of the relevance of these items is that these references were cited by the International Patent Office in the corresponding International Application

Docket No. 4501-1016 Appln. No. 10/530,209

Serial No. PCT/NZ2003/000222. A copy of the International Search Report in which they were cited is attached hereto.

Respectfully submitted,

YOUNG & THOMPSON

Robert J. Patch, Reg. No. 17,355

745 South 23<sup>rd</sup> Street Arlington, VA 22202 Telephone (703) 521-2297 Telefax (703) 685-0573

(703) 979-4709

RJP/psf July 5, 2005

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Attorney Docket No.: **4501-1016** 

pplication No.: 10/530,209

0,209

Applicant:

CAMPBELL et al.

JUL 0 5 2009

(Use several sheets if necessary)

Filing Date:

Group Art Unit: 1615

						April 4, 2005		1615	(A)	& TRAI
			U	J.S. PAT	ENT	DOCUMENTS	<u> </u>			O INAI
Examine Initial	r C	Occument Number		Date		Name	Class	Subclass	Filing (if appro	
IIIIIIaI									(п арріо	priate
· · · · · · · · · · · · · · · · · · ·						A				
					1	· · · · · · · · · · · · · · · · · · ·				···
					<del></del>					
					<del> </del>					
					1					
	_				<del> </del>					
•		<del></del> .								
					<del> </del>					
								-		
	-				<del> </del>					
			F	OREIGN I	PATE	NT DOCUMENTS	_	_		
Examiner Initial	Document Number		Date	)	Country	Clas	s Subclass		lation	
7111101	WO 01/00047 A1			01/04/2001		WIPO			Yes	No
										-
								<u> </u>		
	<del></del>			-	_	hor, Title, Date, Pertine	•	•		
		Jim Mann and Murray Skeaff, "β-casein variants and atherosclerosis – claims are premature", Atherosclerosis, Vol. 170, No. 1, September 2003, pp. 11-12								
	٦	Tailford et al. "A case	in var	iant in cov		lk is atherogenic", Athero	sclerosis, '	√ol. 170, N	o. 1,	-
		September 2003, pp. Beales et al. "A multi-	centre	e. blinded	intern	ational trial of the effect	of A1 and A	√2 β-casein	variant	s on
	0	diabetes incidence in	two re	odent mod	lels of	spontaneous Type I dia	betes", Dia	betologia, \	√ol. 45,	No.
-	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	), September 2002, p McLachlan C.N.S. "β-	g. 124 ∙casei	40-1246 n A <sup>1</sup> . ischa	emic	heart disease mortality,	and other i	llnesses". I	Medical	
		Hypotheses, Vol. 56,								
-			<del>.</del>							
]										
EXAMIN	IER:	W-W				ATE CONSIDERED				-
- V CONTINA	L 1 \.				יט ו	THE CONSIDERED				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.